Yahoo
NasdaqGM - Delayed Quote USD

Tevogen Inc. (TVGN)

7.06 +0.57 (+8.78%)
At close: 4:00:00 PM EDT
Chart Range Bar
Loading chart for TVGN
  • Previous Close 6.49
  • Open 6.68
  • Bid 4.83 x 200
  • Ask 8.30 x 200
  • Day's Range 5.87 - 7.43
  • 52 Week Range 3.64 - 39.00
  • Volume 30,181
  • Avg. Volume 9,748
  • Market Cap (intraday) 45.971M
  • Beta (5Y Monthly) 0.20
  • PE Ratio (TTM) --
  • EPS (TTM) -6.74
  • Earnings Date (est.) Nov 13, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.

tevogen.com

18

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TVGN
57.34%
S&P 500 (^GSPC)
13.44%

1-Year Return

TVGN
80.50%
S&P 500 (^GSPC)
14.98%

3-Year Return

TVGN
98.70%
S&P 500 (^GSPC)
80.23%

5-Year Return

TVGN
98.55%
S&P 500 (^GSPC)
76.83%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -4.68M
Profit Margin 0.00%

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-10M
-8M
-6M
-4M
-2M
0
0.0%

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    50.86M

  • Enterprise Value

    68.02M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -297.37%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -22.24M

  • Diluted EPS (ttm)

    -6.74

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.08M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.05M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

7.06 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: